clinical trial · NCT06362668
EU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System (FASTR-EU)
Reprieve Cardiovascular, Inc·N/A·completed·n = 12
Acute Decompensated Heart FailureReprieve Decongestion Management SystemDiuretic (furosemide, bumetanide, torsemide, hydrochlorothiazide, and/or acetazolamide)
brief summary
The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve DMS system to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve DMS is non-inferior to state-of-the-art urine sodium guided aggressive diuretic titration in two European HF centers of excellence.
started
May 17, 2024
primary completion
Oct 1, 2024
completion
Oct 31, 2024
last updated
Mar 10, 2025
official title
EU Sites: Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS) (FASTR-EU)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol